StockData

Tessera Defense & Homeland Security Inc. (HLSQ) company profile

HLSQOTCServices-Prepackaged SoftwareFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 3/30
$0.11−0.02 (-15.38%)

Close on Nov 9, 2026Market cap $2.94MP/E –Yield –

About Tessera Defense & Homeland Security

Services-Prepackaged Software, SIC 7372

BiomX Inc. is a clinical-stage biotechnology company that develops therapies using natural and synthetic bacteriophage technologies. Its phage treatments are engineered to target and eliminate specific pathogenic bacteria associated with chronic medical conditions, particularly diabetic foot infections. The company's pipeline includes fixed multi-phage cocktails such as BX011 and personalized phage approaches like BX211, both designed to combat Staphylococcus aureus infections. These therapeutic candidates serve patient populations suffering from diabetic foot ulcers and diabetic foot osteomyelitis, offering alternatives or complements to conventional antibiotic regimens.

The company maintains its principal executive offices in Dover, Delaware, and holds Delaware corporate registration. Historically, core operations and personnel were situated in Israel through its subsidiary, BiomX Ltd., which entered insolvency proceedings. BiomX has concentrated its clinical and preclinical studies on bacterial targets across the United States and international markets, while also collaborating with entities such as the U.S. Defense Health Agency and the National Institutes of Health.

Summary of the business section of Tessera Defense & Homeland Security's latest annual report, written by StockData.

Company profile

Company

Legal name
Tessera Defense & Homeland Security Inc.
Headquarters
Dover, DE
Address
850 New Burton Road, Suite 201 19904
Phone
972 545610935
Employees
20, Dec 31, 2025
Industry
Services-Prepackaged Software
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Kesselman & Kesselman, Tel-Aviv, Israel

Stock & identifiers

Ticker
HLSQ
Former tickers
PHGE until Sep 15, 2026; CHAC until Aug 16, 2021
Exchange
OTC
IPO date
Dec 14, 2018
Shares outstanding
27M, Aug 18, 2026
Public float
$11.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Sep 9, 2026; 1-for-17.33 reverse, Feb 19, 2026; 1-for-19 reverse, Nov 25, 2025; 1-for-10 reverse, Aug 26, 2024
SEC CIK
1739174
CUSIP
09090D608
ISIN
US09090D6085
FIGI
BBG00MNX7SQ6
Share class FIGI
BBG00MNX7SR5
EIN
82-3364020

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jonathan Eitan SolomonChief Executive Officer, Director126,748
Merav BassanChief Development Officer79,597
Marina WolfsonChief Financial Officer68,545
Reuven YeganehDirector0
Liat Cohavi BidasDirector–
James E. FlynnDirector–
Deerfield Healthcare Innovations Fund II, L.P.Director–
Deerfield Mgmt V, L.P.Director–
Deerfield Private Design Fund V, L.P.Director–
Deerfield Mgmt HIF, L.P.Director17,876,098
Deerfield Management Company, L.P.Director2,494,108
Russell GreigDirector3,750
Jonathan S. LeffDirector–
Eddie WilliamsDirector–
Jesse GoodmanDirector–
Susan BlumDirector–
Alan Charles MosesDirector5,000
Gregory Louis MerrilDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024$1.08M$811.28K$442.27K$5–
FY2023$1.12M$839.57K$509.59K$12–
FY2022$1.04M$329.66K$479.60K$18–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsOtherTotalvs. prior year
Jonathan Solomon
Chief Executive Officer
$453.32K$70.73K$639.34K$211.64K$1.38M+27%
Marina Wolfson
Chief Financial Officer
$249.10K$38.25K$164.77K$101.34K$553.45K+57%
Dr. Merav Bassan
Chief Development Officer
$285.01K$44.42K$165.61K$147.30K$642.33K+21%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Dec 14, 2018
Offer price
$10.00
Securities offered
7,000,000
Gross proceeds
$70.00M
Exchange
NYSE American
First trading day
Mar 13, 2019
Lock-up ends (est.)
Sep 9, 2019

“We are offering 7,000,000 units at an offering price of $10.00 per unit.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 20 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 9, 2026Name changeName changed from BiomX Inc. to Tessera Defense & Homeland Security Inc.
Aug 14, 2026Late filingNotification of late filing
Jul 2, 2026Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 12, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 15, 2026Late filingNotification of late filing
Apr 13, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 10, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 27, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 10, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 31, 2024DeregistrationTermination of SEC registration (Form 15)
Oct 25, 2024DelistingNotice of delisting from exchange (Form 25)
Oct 15, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 29, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 30, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 15, 2024Late filingNotification of late filing
Apr 1, 2024Late filingNotification of late filing
Mar 18, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 12, 2023DelistingNotice of delisting from exchange (Form 25)
Jun 8, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 18, 2021Late filingNotification of late filing
Apr 29, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 4, 2019Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 4, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 1, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 1, 2019Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 23, 2019Name changeName changed from Chardan Healthcare Acquisition Corp. to BiomX Inc.
Sep 24, 2019Merger voteDefinitive merger proxy statement
Dec 14, 2018IPOInitial public offering priced (424B4 prospectus)
Dec 13, 2018ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?